NNIT A/S

LSE:0R5Z Stock Report

Market Cap: DKK 2.3b

NNIT Valuation

Is 0R5Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R5Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0R5Z (DKK90.3) is trading below our estimate of fair value (DKK283.2)

Significantly Below Fair Value: 0R5Z is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R5Z?

Key metric: As 0R5Z is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0R5Z. This is calculated by dividing 0R5Z's market cap by their current earnings.
What is 0R5Z's PE Ratio?
PE Ratio31.2x
EarningsDKK 73.00m
Market CapDKK 2.28b

Price to Earnings Ratio vs Peers

How does 0R5Z's PE Ratio compare to its peers?

The above table shows the PE ratio for 0R5Z vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.9x
INS Instem
59.8xn/aUK£199.6m
EMIS EMIS Group
40.4x11.0%UK£1.2b
CRW Craneware
89.1x24.3%UK£822.9m
IDHC Integrated Diagnostics Holdings
14.3x23.7%US$234.9m
0R5Z NNIT
31.2x47.8%DKK 2.3b

Price-To-Earnings vs Peers: 0R5Z is good value based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (51.7x).

Price to Earnings Ratio vs Industry

How does 0R5Z's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0R5Z 31.2xIndustry Avg. 18.0xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0R5Z is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the European Healthcare Services industry average (18x).

Price to Earnings Ratio vs Fair Ratio

What is 0R5Z's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R5Z PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.2x
Fair PE Ratio49.1x

Price-To-Earnings vs Fair Ratio: 0R5Z is good value based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (49.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R5Z forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 90.30
DKK 122.50
+35.7%
14.3%DKK 140.00DKK 105.00n/a2
Nov ’25DKK 104.20
DKK 142.50
+36.8%
5.3%DKK 150.00DKK 135.00n/a2
Oct ’25DKK 126.30
DKK 142.50
+12.8%
5.3%DKK 150.00DKK 135.00n/a2
Sep ’25DKK 105.80
DKK 142.50
+34.7%
5.3%DKK 150.00DKK 135.00n/a2
Aug ’25DKK 106.50
DKK 137.50
+29.1%
1.8%DKK 140.00DKK 135.00n/a2
Jul ’25DKK 106.00
DKK 137.50
+29.7%
1.8%DKK 140.00DKK 135.00n/a2
Jun ’25DKK 108.80
DKK 137.50
+26.4%
1.8%DKK 140.00DKK 135.00n/a2
May ’25DKK 105.40
DKK 137.50
+30.5%
1.8%DKK 140.00DKK 135.00n/a2
Apr ’25DKK 109.20
DKK 105.00
-3.8%
33.3%DKK 140.00DKK 70.00n/a2
Mar ’25DKK 103.80
DKK 105.00
+1.2%
33.3%DKK 140.00DKK 70.00n/a2
Feb ’25DKK 97.01
DKK 95.00
-2.1%
26.3%DKK 120.00DKK 70.00n/a2
Jan ’25DKK 84.10
DKK 95.00
+13.0%
26.3%DKK 120.00DKK 70.00n/a2
Dec ’24DKK 86.80
DKK 95.00
+9.4%
26.3%DKK 120.00DKK 70.00n/a2
Nov ’24DKK 80.20
DKK 95.00
+18.5%
26.3%DKK 120.00DKK 70.00DKK 104.202
Oct ’24DKK 85.15
DKK 95.00
+11.6%
26.3%DKK 120.00DKK 70.00DKK 126.302
Sep ’24DKK 82.80
DKK 95.00
+14.7%
26.3%DKK 120.00DKK 70.00DKK 105.802
Aug ’24DKK 81.05
DKK 95.00
+17.2%
26.3%DKK 120.00DKK 70.00DKK 106.502
Jul ’24DKK 80.20
DKK 95.00
+18.5%
26.3%DKK 120.00DKK 70.00DKK 106.002
Jun ’24DKK 86.60
DKK 95.00
+9.7%
26.3%DKK 120.00DKK 70.00DKK 108.802
May ’24DKK 74.99
DKK 95.00
+26.7%
26.3%DKK 120.00DKK 70.00DKK 105.402
Apr ’24DKK 69.30
DKK 95.00
+37.1%
26.3%DKK 120.00DKK 70.00DKK 109.202
Mar ’24DKK 70.10
DKK 90.00
+28.4%
33.3%DKK 120.00DKK 60.00DKK 103.802
Feb ’24DKK 68.90
DKK 90.00
+30.6%
33.3%DKK 120.00DKK 60.00DKK 97.012
Jan ’24DKK 64.80
DKK 90.00
+38.9%
33.3%DKK 120.00DKK 60.00DKK 84.102
Dec ’23DKK 64.60
DKK 90.00
+39.3%
33.3%DKK 120.00DKK 60.00DKK 86.802
Nov ’23DKK 56.30
DKK 90.00
+59.9%
33.3%DKK 120.00DKK 60.00DKK 80.202

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$403.49

7D

0.4%

1Y

-15.5%

Kooth

UK£64.8m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.78

7D

7.6%

1Y

-40.4%

Enovis

US$2.7b

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

0I1B

US$48.46

7D

9.7%

1Y

-3.3%